Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Feb;40(2):393–399. doi: 10.1128/aac.40.2.393

Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.

B Ji 1, E G Perani 1, C Petinom 1, J H Grosset 1
PMCID: PMC163122  PMID: 8834886

Abstract

The bactericidal activities of 12 regimens with various combinations of new drugs (clarithromycin [CLARI], minocycline [MINO], and ofloxacin [OFLO]) and the standard antileprosy drugs, especially rifampin (RMP), were compared in nude mice with established Mycobacterium leprae infection. The longest duration of treatment was 24 weeks for intermittent (once every 4 weeks) therapy and 8 weeks for daily therapy. Bactericidal effects were monitored by titrating the proportion of viable M. leprae isolates by subinoculating the organisms into the footpads of immunocompetent and nude mice. The results indicate that RMP was more bactericidal than any combination of the new drugs. A single dose of CLARI-MINO, with or without OFLO, displayed bactericidal activity as great as that of 4 weeks of daily treatment with dapsone (DDS) plus clofazimine (CLO); thus, intermittent CLARI-MINO, with or without OFLO, may replace DDS and CLO of the standard multidrug regimen, and these will become regimens that can be administered monthly and under full supervision. Additional evidence that this may be the case is provided by the finding that intermittent RMP-CLARI-MINO or RMP-CLARI-MINO-OFLO administered for 12 or 24 weeks was as active as the standard multidrug regimen. While the intermittent treatment always displayed significantly greater bactericidal activity than the same number of doses of daily treatment, daily treatment with CLARI-MINO and CLARI-MINO-OFLO were more active than the drugs given as intermittent treatment for the same duration; therefore, unless these combinations are to be administered together with intermittent RMP, they should be given daily, especially for the treatment of RMP-resistant cases of infection. Finally, 12 weeks of daily treatment with DDS-CLO was more bactericidal than had been expected, suggesting that it may not be necessary to administer the standard multidrug regimen for multibacillary leprosy for as long as 24 months in order to minimize the risk of developing RMP resistance.

Full Text

The Full Text of this article is available as a PDF (198.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Franzblau S. G., Hastings R. C. In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother. 1988 Dec;32(12):1758–1762. doi: 10.1128/aac.32.12.1758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gelber R. H. Activity of minocycline in Mycobacterium leprae-infected mice. J Infect Dis. 1987 Jul;156(1):236–239. doi: 10.1093/infdis/156.1.236. [DOI] [PubMed] [Google Scholar]
  3. Gelber R. H., Fukuda K., Byrd S., Murray L. P., Siu P., Tsang M., Rea T. H. A clinical trial of minocycline in lepromatous leprosy. BMJ. 1992 Jan 11;304(6819):91–92. doi: 10.1136/bmj.304.6819.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Grosset J. H., Guelpa-Lauras C. C., Perani E. G., Beoletto C. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis. 1988 Jun;56(2):259–264. [PubMed] [Google Scholar]
  5. Grosset J. H., Ji B. H., Guelpa-Lauras C. C., Perani E. G., N'Deli L. N. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1990 Jun;58(2):281–295. [PubMed] [Google Scholar]
  6. Husser J. A., Traore I., Daumerie D. Activity of two doses of rifampin against Mycobacterium leprae. Int J Lepr Other Mycobact Dis. 1994 Sep;62(3):359–364. [PubMed] [Google Scholar]
  7. Jamet P., Ji B. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis. 1995 Jun;63(2):195–201. [PubMed] [Google Scholar]
  8. Ji B., Grosset J. H. Recent advances in the chemotherapy of leprosy. Lepr Rev. 1990 Dec;61(4):313–329. doi: 10.5935/0305-7518.19900029. [DOI] [PubMed] [Google Scholar]
  9. Ji B., Jamet P., Perani E. G., Bobin P., Grosset J. H. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis. 1993 Jul;168(1):188–190. doi: 10.1093/infdis/168.1.188. [DOI] [PubMed] [Google Scholar]
  10. Ji B., Perani E. G., Grosset J. H. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother. 1991 Mar;35(3):579–581. doi: 10.1128/aac.35.3.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ji B., Perani E. G., Petinom C., N'Deli L., Grosset J. H. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother. 1994 Apr;38(4):662–667. doi: 10.1128/aac.38.4.662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ji B., Perani E. G., Petinon C., Grosset J. H. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. Int J Lepr Other Mycobact Dis. 1992 Dec;60(4):556–561. [PubMed] [Google Scholar]
  13. Levy L., Shepard C. C., Fasal P. The bactericidal effect of rifampicin on M. leprae in man: a) single doses of 600, 900 and 1200 mg; and b) daily doses of 300 mg. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):183–187. [PubMed] [Google Scholar]
  14. McDermott-Lancaster R. D., Ito T., Kohsaka K., Guelpa-Lauras C. C., Grosset J. H. Multiplication of Mycobacterium leprae in the nude mouse, and some applications of nude mice to experimental leprosy. Int J Lepr Other Mycobact Dis. 1987 Dec;55(4 Suppl):889–895. [PubMed] [Google Scholar]
  15. Rao P. S., Ramachandran A., Sekar B., Ravi S., Subramanian M. Ofloxacin-containing combined drug regimens in the treatment of lepromatous leprosy. Lepr Rev. 1994 Sep;65(3):181–189. doi: 10.5935/0305-7518.19940018. [DOI] [PubMed] [Google Scholar]
  16. SHEPARD C. C., MCRAE D. H. MYCOBACTERIUM LEPRAE IN MICE: MINIMAL INFECTIOUS DOSE, RELATIONSHIP BETWEEN STAINING QUALITY AND INFECTIVITY, AND EFFECT OF CORTISONE. J Bacteriol. 1965 Feb;89:365–372. doi: 10.1128/jb.89.2.365-372.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Shepard C. C. Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae. Int J Lepr Other Mycobact Dis. 1982 Mar;50(1):96–101. [PubMed] [Google Scholar]
  18. Xiong J. H., Ji B., Perani E. G., Pétinon C., Grosset J. H. Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis. 1994 Mar;62(1):37–42. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES